Skip to content
Bored Studies
RecruitingPhase 3

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

MBX Biosciences · NCT07699471

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
160
US sites recruiting
20
Study start
August 26, 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).

Being studied: Canvuparatide; Placebo

Conditions: Hypoparathyroidism

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Is an adult ≥18 years of age.
  • Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or autoimmune HypoPT for at least 12 months prior to screening.
  • Intact PTH level below the median value of the normal range
  • Minimum requirement for a dose of calcitriol ≥0.5 μg/day, or alfacalcidol ≥1.0 μg/day and (elemental) calcium ≥1000 mg/day for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.
  • Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg/dL (1.95 to 2.35 mmol/L).

Key Exclusion Criteria

  • Has a known history of pseudohypoparathyroidism
  • Clinically significant abnormal hematology, clinical chemistry, or coagulation.
  • Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism;
  • Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization
  • PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.

Recruiting US locations

Study contacts (from the official record)

  • Salomon Azoulay, MD · 13176590200
A Study to Investigate Canvuparatide Compared With Placebo in… (NCT07699471) | Bored Studies